Unknown PHASE2 INTERVENTIONAL 2-arm NCT04252365

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

A Randomized Controlled, Phase II Trial Comparing Sintilimab and Pembrolizumab at First-line Setting in Patients With Advanced Non-small Cell Lung Cancer

Sponsor: Guangdong Association of Clinical Trials

Conditions Nsclc

Interventions Pembrolizumab Sintilimab

Updated 5 times since 2020 Last updated: Jan 31, 2020 Started: Mar 1, 2020 Primary completion: Mar 1, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Nsclc and is currently ongoing. Guangdong Association of Clinical Trials leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2
Mar 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Association of Clinical Trials

Data source: Guangdong Association of Clinical Trials

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.